Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$34.68
-$0.03(-0.12%)
At close: 4:00 PM EST
$34.68
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$21.14 - $42.21
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.01M
Market Cap
$3.70B
Enterprise Value$3.07B
Total Cash (Recent Filing)$636.11M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding116,903,980
10 Day Avg. Volume791,946
30 Day Avg. Volume1,011,774
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue135.92
Enterprise Value/Gross Profit139.37
Enterprise Value/Ebitda-14.43
Forecast
1Y Price Target
$49.00Price Target Upside41.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$29.46M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMinimal debt versus a large equity base gives durable solvency and financial flexibility. This conservative capital structure reduces bankruptcy and refinancing risk, allowing the company to fund clinical development and strategic options over multiple quarters without immediate debt pressure.
High Gross MarginsVery high gross margins reflect low direct cost structure typical of clinical-stage biotech. If clinical success and approvals occur, those margins create strong operating leverage, enabling scalable profitability as revenues grow and fixed R&D and SG&A costs are absorbed.
Governance And Employee AlignmentApproval of an ESPP, continuity in audit and board oversight, and extended issuance authority improve employee retention, governance stability, and capital-raising optionality. These structural changes aid long-term talent alignment and provide organized flexibility for funding programs.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this magnitude creates a structural runway constraint. The company will likely need external capital or partnerships, increasing dilution or conditionality on strategic deals and constraining discretionary investments over the medium term.
Deep Net LossesExtremely negative net margins and returns signal that operations do not generate positive shareholder returns today. This structural unprofitability limits reinvestment from operations, heightens dependence on markets or partners, and raises the bar for commercialization to achieve sustainable earnings.
Revenue Volatility And Low ScaleMaterial year-on-year revenue decline and small absolute sales indicate lack of commercial scale and volatile revenue sources. This undermines the company's ability to absorb fixed costs and makes margin improvements contingent on clinical/regulatory success rather than recurring, diversified revenues.
NewAmsterdam Pharma Company News
NAMS FAQ
What was Newamsterdam Pharma Company N.V.’s price range in the past 12 months?
Newamsterdam Pharma Company N.V. lowest stock price was $21.14 and its highest was $42.20 in the past 12 months.
What is Newamsterdam Pharma Company N.V.’s market cap?
Newamsterdam Pharma Company N.V.’s market cap is $3.70B.
When is Newamsterdam Pharma Company N.V.’s upcoming earnings report date?
Newamsterdam Pharma Company N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Newamsterdam Pharma Company N.V.’s earnings last quarter?
Newamsterdam Pharma Company N.V. released its earnings results on May 07, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.059.
Is Newamsterdam Pharma Company N.V. overvalued?
According to Wall Street analysts Newamsterdam Pharma Company N.V.’s price is currently Undervalued.
Does Newamsterdam Pharma Company N.V. pay dividends?
Newamsterdam Pharma Company N.V. does not currently pay dividends.
What is Newamsterdam Pharma Company N.V.’s EPS estimate?
Newamsterdam Pharma Company N.V.’s EPS estimate is -0.48.
How many shares outstanding does Newamsterdam Pharma Company N.V. have?
Newamsterdam Pharma Company N.V. has 116,903,980 shares outstanding.
What happened to Newamsterdam Pharma Company N.V.’s price movement after its last earnings report?
Newamsterdam Pharma Company N.V. reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 12.456%.
Which hedge fund is a major shareholder of Newamsterdam Pharma Company N.V.?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (41.29% Upside)
$49.00 (41.29% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 386.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.48%
Trailing 12-Months
Company Description
Newamsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$49.00
▲(41.29% Upside)
Technical Analysis
Ownership Overview
6.18% Insiders
22.46% Mutual Funds
0.30% Other Institutional Investors
69.22% Public Companies and
Individual Investors